Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
141 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Ebola Viral Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Ebola Viral Infections - Pipeline Review, H2 2014', provides an overview of the Ebola Viral Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Ebola Viral Infections Overview 7 Therapeutics Development 8 Pipeline Products for Ebola Viral Infections - Overview 8 Pipeline Products for Ebola Viral Infections - Comparative Analysis 9 Ebola Viral Infections - Therapeutics under Development by Companies 10 Ebola Viral Infections - Therapeutics under Investigation by Universities/Institutes 12 Ebola Viral Infections - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Ebola Viral Infections - Products under Development by Companies 17 Ebola Viral Infections - Products under Investigation by Universities/Institutes 18 Ebola Viral Infections - Companies Involved in Therapeutics Development 19 GlaxoSmithKline plc 19 Tekmira Pharmaceuticals Corp. 20 Inovio Pharmaceuticals, Inc. 21 Bavarian Nordic A/S 22 Toyama Chemical Co., Ltd. 23 Crucell N.V. 24 Medicago Inc. 25 NanoViricides, Inc. 26 BioCryst Pharmaceuticals, Inc. 27 Summit Corporation plc 28 AlphaVax, Inc. 29 Chimerix, Inc. 30 Microbiotix, Inc. 31 Immunovaccine, Inc. 32 Integrated BioTherapeutics, Inc. 33 Vaxart, Inc. 34 Profectus BioSciences, Inc. 35 Navigen Pharmaceuticals, Inc. 36 Inhibikase Therapeutics, Inc. 37 Humabs BioMed SA 38 Mapp Biopharmaceutical, Inc. 39 NewLink Genetics Corporation 40 Epirus Biopharmaceuticals, Inc. 41 Ebola Viral Infections - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Combination Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 Recombinant Vector Vaccine for Multivalent Filovirus - Drug Profile 52 TKM-100802 - Drug Profile 54 Ebola Vaccine + Marburg Vaccine - Drug Profile 57 Ebola Vaccine - Drug Profile 58 brincidofovir - Drug Profile 60 favipiravir - Drug Profile 62 Filovirus Vaccine - Drug Profile 64 Drugs for Ebola and Marburg Infections - Drug Profile 65 SMT-15000 - Drug Profile 66 panfilovirus vaccine - Drug Profile 67 BCX-4430 - Drug Profile 68 ebola vaccine - Drug Profile 70 ebola vaccine - Drug Profile 71 ET-007 - Drug Profile 72 ZMapp - Drug Profile 73 Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - Drug Profile 75 ZMAb - Drug Profile 76 MVA-BN-Filoviruses Vaccine - Drug Profile 78 Small Molecules to Target Estrogen Receptor for Ebola Virus Infection - Drug Profile 79 ebola virus vaccine - Drug Profile 80 ebola and marburg vaccine (trivalent) - Drug Profile 81 TKM-100701 - Drug Profile 82 MMCatLMC - Drug Profile 83 ebola vaccine - Drug Profile 84 ebola vaccine - Drug Profile 86 ebola and marburg + rabies vaccine - Drug Profile 87 Monoclonal Antibodies for Viral Infections - Drug Profile 88 ebola vaccine - Drug Profile 90 ebola vaccine [zaire] - Drug Profile 91 ebola (virus like particles) vaccine - Drug Profile 92 imatinib mesylate - Drug Profile 93 oxocarbazate - Drug Profile 94 thiocarbazate - Drug Profile 95 Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Drug Profile 96 Monoclonal Antibody for Ebola Virus Infections - Drug Profile 97 Small Molecules to Inhibit Niemann Pick C1 for Ebola Viral Infections - Drug Profile 98 EMER-IT - Drug Profile 99 Ebola Vaccine - Drug Profile 100 Synthetic Peptides for Ebola Virus - Drug Profile 101 Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 102 Small Molecules to Inhibit SAH Hydrolase for Ebola Virus Infection - Drug Profile 103 Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection - Drug Profile 104 ARD-5 - Drug Profile 105 1-E703 - Drug Profile 106 Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 107 ebola vaccine - Drug Profile 108 ebola and marburg vaccine- Drug Profile 109 Ebola Viral Infections - Recent Pipeline Updates 110 Ebola Viral Infections - Dormant Projects 125 Ebola Viral Infections - Discontinued Products 126 Ebola Viral Infections - Product Development Milestones 127 Featured News & Press Releases 127 Appendix 136 Methodology 136 Coverage 136 Secondary Research 136 Primary Research 136 Expert Panel Validation 136 Contact Us 137 Disclaimer 137
List of Tables Number of Products under Development for Ebola Viral Infections, H2 2014 12 Number of Products under Development for Ebola Viral Infections - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 14 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 18 Comparative Analysis by Early Stage Development, H2 2014 19 Comparative Analysis by Unknown Stage Development, H2 2014 20 Products under Development by Companies, H2 2014 21 Products under Investigation by Universities/Institutes, H2 2014 22 Ebola Viral Infections - Pipeline by GlaxoSmithKline plc, H2 2014 23 Ebola Viral Infections - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 24 Ebola Viral Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 25 Ebola Viral Infections - Pipeline by Bavarian Nordic A/S, H2 2014 26 Ebola Viral Infections - Pipeline by Toyama Chemical Co., Ltd., H2 2014 27 Ebola Viral Infections - Pipeline by Crucell N.V., H2 2014 28 Ebola Viral Infections - Pipeline by Medicago Inc., H2 2014 29 Ebola Viral Infections - Pipeline by NanoViricides, Inc., H2 2014 30 Ebola Viral Infections - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2014 31 Ebola Viral Infections - Pipeline by Summit Corporation plc, H2 2014 32 Ebola Viral Infections - Pipeline by AlphaVax, Inc., H2 2014 33 Ebola Viral Infections - Pipeline by Chimerix, Inc., H2 2014 34 Ebola Viral Infections - Pipeline by Microbiotix, Inc., H2 2014 35 Ebola Viral Infections - Pipeline by Immunovaccine, Inc., H2 2014 36 Ebola Viral Infections - Pipeline by Integrated BioTherapeutics, Inc., H2 2014 37 Ebola Viral Infections - Pipeline by Vaxart, Inc., H2 2014 38 Ebola Viral Infections - Pipeline by Profectus BioSciences, Inc., H2 2014 39 Ebola Viral Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 40 Ebola Viral Infections - Pipeline by Inhibikase Therapeutics, Inc., H2 2014 41 Ebola Viral Infections - Pipeline by Humabs BioMed SA, H2 2014 42 Ebola Viral Infections - Pipeline by Mapp Biopharmaceutical, Inc., H2 2014 43 Ebola Viral Infections - Pipeline by NewLink Genetics Corporation, H2 2014 44 Ebola Viral Infections - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 45 Assessment by Monotherapy Products, H2 2014 46 Assessment by Combination Products, H2 2014 47 Number of Products by Stage and Target, H2 2014 49 Number of Products by Stage and Mechanism of Action, H2 2014 51 Number of Products by Stage and Route of Administration, H2 2014 53 Number of Products by Stage and Molecule Type, H2 2014 55 Ebola Viral Infections Therapeutics - Recent Pipeline Updates, H2 2014 114 Ebola Viral Infections - Dormant Projects, H2 2014 129 Ebola Viral Infections - Discontinued Products, H2 2014 130
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
